Is 1 ml of testosterone (via intramuscular injection) safe to administer in the deltoid muscle for an adult male patient with hypogonadism?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 8, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Is 1 mL of Testosterone Safe for Deltoid Injection?

Yes, 1 mL of testosterone is safe to administer in the deltoid muscle for intramuscular injection, though the FDA-approved label specifically recommends deep gluteal muscle injection as the preferred site. 1

FDA-Approved Administration Guidelines

  • The FDA label for testosterone cypionate explicitly states "intramuscular injections should be given deep in the gluteal muscle" as the standard route of administration 1
  • The approved dosage range is 50-400 mg every 2-4 weeks for hypogonadal males, which typically corresponds to 0.25-2 mL volume depending on concentration 1
  • No specific contraindication exists for deltoid administration in the FDA labeling, though gluteal injection is the documented preferred site 1

Clinical Practice Considerations

Volume and injection site selection:

  • A 1 mL volume falls well within the acceptable range for deltoid intramuscular injection from a technical standpoint, as the deltoid can accommodate up to 2 mL in most adult males 2
  • The most common formulations (testosterone cypionate or enanthate) are typically 200 mg/mL concentration, meaning 1 mL delivers 200 mg—a standard replacement dose 3, 1
  • Intramuscular testosterone injections are administered every 2-3 weeks, with peak serum levels occurring 2-5 days after injection 3

Practical advantages of deltoid vs. gluteal injection:

  • Deltoid injection allows for self-administration, which improves patient autonomy and reduces healthcare visit requirements 3
  • The gluteal site, while FDA-recommended, often requires assistance from another person for proper administration 4
  • Patient preference studies show that convenience and ease of self-administration are major factors in treatment adherence 5, 3

Alternative Injection Routes

Subcutaneous administration as an emerging option:

  • Recent evidence demonstrates that subcutaneous testosterone injections (typically 50-150 mg weekly) are effective and safe, achieving normal male testosterone levels across a wide BMI range (19.0-49.9 kg/m²) 4
  • Among 22 patients who switched from intramuscular to subcutaneous, all had mild (n=2) or marked (n=20) preference for subcutaneous injections, with none preferring intramuscular 4
  • Subcutaneous injections involve significantly less discomfort and allow easier self-administration 4

Monitoring Requirements

  • Testosterone levels should be measured midway between injections (days 5-7 after injection for cypionate/enanthate), targeting mid-normal values of 500-600 ng/dL 3
  • Monitor hematocrit periodically and withhold treatment if >54%, as intramuscular testosterone carries higher erythrocytosis risk compared to transdermal preparations 3, 6
  • Check PSA in men over 40 years before initiating therapy and monitor for significant increases during treatment 3

Common Pitfalls to Avoid

  • Never inject intravenously—testosterone cypionate is for intramuscular or subcutaneous use only 1
  • Avoid injecting cold solution, as crystals may have formed during storage; warming and shaking the vial should redissolve any crystals 1
  • Do not use testosterone therapy in men actively seeking fertility, as it suppresses spermatogenesis and causes azoospermia—gonadotropin therapy is mandatory instead 3
  • Ensure confirmed biochemical hypogonadism (morning total testosterone <300 ng/dL on two separate occasions) before initiating therapy 3

References

Research

Male hypogonadism : an update on diagnosis and treatment.

Treatments in endocrinology, 2005

Guideline

Testosterone Injection Treatment for Male Hypogonadism

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Testosterone Undecanoate Therapy for Hypogonadism

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.